Kybella to improve your profile
The only FDA-approved injectable treatment that destroys fat cells in the submental area, commonly referred to as a double-chin to improve your profile.
How does it work? The active ingredient in Kybella is made of a synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body. This molecule works to breakdown and then absorb fat. Kybella when injected into the double chin fat area destroys the fat cells. Once they are destroyed, these cells can no longer accumulate fat.
Kybella is right for you if you answer yes to any of these statements:
Your double chin makes you sad
Your chin makes you look older than you are
You don't want to have surgery
Despite diet and exercise your double chin won't disappear
What to expect? The entire treatment is relatively painless. An ice compress will be applied to the entire area to be treated. This helps to reduce any swelling as well as make it more comfortable for the patient. The area will be sterilized and marked. Then our medical professional will perform a series of injections within the area. Some patients experience a "heat" sensation, redness and swelling after the treatment. If needed, patients may take ibuprofen (if able to tolerate) to minimize any discomfort. In 4 weeks this process is repeated.
Marina before Kybella treatment
Marina midway thru Kybella
Marina after Kybella treatment
KYBELLA® (deoxycholic acid) injection 10 mg/mLIndication and Important Safety Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Contraindications
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
Adverse Reactions
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full prescribing information.
Request your complimentary consultation
203.903.1455 | info@clarityct.com
1205 Boston Post Rd Guilford | 2456 Whitney Ave Hamden
Medical Director: DR. Stephen A. Brown -
Board Certified Plastic Surgeon